Titan Retained Earnings Total Equity from 2010 to 2024

TTNP Stock  USD 6.64  0.42  5.95%   
Titan Pharmaceuticals Retained Earnings Total Equity yearly trend continues to be relatively stable with very little volatility. Retained Earnings Total Equity is likely to drop to about -347.1 M. Retained Earnings Total Equity is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. View All Fundamentals
 
Retained Earnings Total Equity  
First Reported
2011-06-30
Previous Quarter
-369.9 M
Current Value
-371.6 M
Quarterly Volatility
138 M
 
Yuan Drop
 
Covid
Check Titan Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Titan Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 106.4 K, Interest Expense of 31.7 K or Total Revenue of 174.8 K, as well as many indicators such as Price To Sales Ratio of 32.03, Dividend Yield of 0.0 or PTB Ratio of 0.89. Titan financial statements analysis is a perfect complement when working with Titan Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Titan Pharmaceuticals Correlation against competitors.
To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.

Latest Titan Pharmaceuticals' Retained Earnings Total Equity Growth Pattern

Below is the plot of the Retained Earnings Total Equity of Titan Pharmaceuticals over the last few years. It is the portion of total equity that consists of earnings retained by the company, reinvested in its core business or used to pay debt. Titan Pharmaceuticals' Retained Earnings Total Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Titan Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Retained Earnings Total Equity10 Years Trend
Slightly volatile
   Retained Earnings Total Equity   
       Timeline  

Titan Retained Earnings Total Equity Regression Statistics

Arithmetic Mean(247,188,917)
Geometric Mean0.00
Coefficient Of Variation(62.97)
Mean Deviation131,834,089
Median(323,271,000)
Standard Deviation155,650,908
Sample Variance24227.2T
Range367.3M
R-Value(0.79)
Mean Square Error9751.4T
R-Squared0.63
Significance0.0004
Slope(27,542,958)
Total Sum of Squares339180.9T

Titan Retained Earnings Total Equity History

2024-347.1 M
2023-330.6 M
2020-367.3 M
2019-349 M
2018-332.6 M
2017-323.3 M
2016-309 M

About Titan Pharmaceuticals Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Titan Pharmaceuticals income statement, its balance sheet, and the statement of cash flows. Titan Pharmaceuticals investors use historical funamental indicators, such as Titan Pharmaceuticals's Retained Earnings Total Equity, to determine how well the company is positioned to perform in the future. Although Titan Pharmaceuticals investors may use each financial statement separately, they are all related. The changes in Titan Pharmaceuticals's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Titan Pharmaceuticals's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Titan Pharmaceuticals Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Titan Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Retained Earnings Total Equity-330.6 M-347.1 M

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect

Additional Tools for Titan Stock Analysis

When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.